AZD9668 Relative Bioavailability

Study identifier:D0520C00017

ClinicalTrials.gov identifier:N/A

EudraCT identifier:N/A

CTIS identifier:N/A

Study Complete

Official Title

A phase I open-label, single-centre, two cohort crossover study to assess the relative bioavailability after oral administration of AZD9668 free base dosed as a suspension compared to AZD9669 tosylate salt dosed as a tablet

Medical condition

Chronic Obstructive Pulmonary Disease

Phase

Phase 1

Healthy volunteers

Yes

Study drug

AZD9668

Sex

All

Actual Enrollment

28

Study type

Interventional

Age

18 Years - 55 Years

Date

Study Start Date: 01 Nov 2009
Primary Completion Date: 01 Dec 2009
Study Completion Date: 01 Dec 2009

Study design

Allocation: Randomized
Endpoint Classification: Bio-availability Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Other

Verification:

Verified 01 Dec 2013 by AstraZeneca Pharmaceuticals

Sponsors

AstraZeneca Pharmaceuticals

Collaborators

-

Inclusion and exclusion criteria